Allergan said proposed generic versions of a treatment for schizophrenia and bipolar disorder by Breckenridge infringe a patent for Saphris.
- Allergan is seeking a court order blocking copies until after the patent has expired, according to complaint filed Monday in federal court in Wilmington, Delaware
- Patent expires in December 2020, complaint says
- Breckenridge sent Allergan a letter dated Dec. 27 announcing its plans to seek FDA approval to sell 2.5 milligram, 5 mg and 10 mg tablets of generic Saphris, complaint says
- Case is related to lawsuits filed in Delaware by Allergan’s Forest unit in 2014 and in 2017 against…